1. The use of "pituitary adenylate cyclase activating peptide" (PACAP) as a vaccine adjuvant for antigenov.2. Use according to claim. 1, where PACAP is administered in form of a peptide or nucleic kisloty.3. Use according to claim. 1, wherein the peptide prepared as PACAP) by isolation from its natural source, b) by chemical synthesis or c) DNK.4 by recombinant technology. Use according to claim. 1, wherein said vaccine antigens used in the prevention of disease caused by infectious agentami.5. Use according to claim. 4, where the disease occur in mammals, fish or ptits.6. Use according to claim. 4, wherein the infectious agent is a virus, bacterium or ektoparazita.7. A vaccine composition comprising "pituitary adenylate cyclase activating peptide" (PACAP), at least one vaccine antigen and a pharmaceutically acceptable carrier or razbaviteli.8. The composition according to claim. 7, which is used for the prevention of diseases caused by infectious agentami.9. The composition of claim. 7, which is administered as a PACAP peptide, obtained a) by separation from a natural source, b) by chemical synthesis or c) DNK.10 by recombinant technology. The composition of claim. 7 where PACAP is administered as a nucleic kisloty.11. Combination vaccine comprising "pituitary adenylate cyclase activating peptide" (PACAP) and at least one vaccine antigen.12. The combination of claim. 11 wherein the PACAP and the antigen are administered simultaneously, separately or sequentially during the same schedule immunizatsii.13. A method of increasing the immune response to the vaccine antigen is characterized by including applying a composition which includes "pituitary ACTIVE1. Применение «питуитарного активирующего аденилатциклазу пептида» (РАСАР) в качестве адъюванта для вакцинных антигенов.2. Применение по п. 1, где РАСАР вводят в форме пептида или нуклеиновой кислоты.3. Применение по п. 1, где пептид РАСАР получают а) путем выделения из его природного источника, b) путем химического с
